Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 4/20 | 0.42 |
| ▸ | CTSS | P25774 | 3/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 2/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 2/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22285129 | 0.84 | CTSS (0.47) | AAK1GAAEPHX1HDAC4HDAC1 | |
| SCHEMBL16317185 | 0.84 | GAA (0.47) | AAK1GAAEPHX1HDAC4HDAC1 | |
| SCHEMBL22285128 | 0.84 | CTSS (0.47) | AAK1GAAEPHX1HDAC4HDAC1 | |
| SCHEMBL8134597 | 0.84 | GAA (0.47) | AAK1GAAEPHX1HDAC4HDAC1 | |
| SCHEMBL844822 | 0.84 | CTSS (0.47) | AAK1GAAEPHX1HDAC4HDAC1 | |
| SCHEMBL23005710 | 0.84 | CTSS (0.47) | AAK1GAAEPHX1HDAC4HDAC1 | |
| SCHEMBL844823 | 0.84 | CTSS (0.47) | AAK1GAAEPHX1HDAC4HDAC1 | |
| SCHEMBL22125910 | 0.84 | CTSS (0.47) | AAK1GAAEPHX1HDAC4HDAC1 | |
| SCHEMBL127389 | 0.84 | CTSS (0.47) | AAK1GAAEPHX1HDAC4HDAC1 | |
| SCHEMBL12018425 | 0.84 | MMP2 (0.44) | AAK1EPHX1CA1CA2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9526769-B2 | Macrocylic oximyl hepatitis C protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2016-12-27 | — | — | US | disclosed |
| US-9526769-B2 | Macrocylic oximyl hepatitis C protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2016-12-27 | — | — | US | disclosed |
| US-8940688-B2 | Fluorinated tripeptide HCV serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-8785377-B2 | Tetrazolyl macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-8785377-B2 | Tetrazolyl macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-8361958-B2 | Oximyl HCV serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-8361958-B2 | Oximyl HCV serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-8268776-B2 | mixture of cytochrome P450 monooxygenase inhibitor and protease inhibitor for anti-hepatitis C viral treatment; including other active drugs as interferon, ribavarin, and adamantine | ENANTA PHARMACEUTICALS, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-8193346-B2 | Process for making macrocyclic oximyl hepatitis C protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-8101567-B2 | Heteroaryl-containing tripeptide HCV serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20090130059-A1 | TETRAZOLYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-05-21 | — | — | US | disclosed |
| US-20090035271-A1 | TETRAZOLYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-02-05 | — | — | US | disclosed |
| US-20090035271-A1 | TETRAZOLYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-02-05 | — | — | US | disclosed |
| US-20080187516-A1 | ACYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-08-07 | — | — | US | disclosed |
| US-20080187516-A1 | ACYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-08-07 | — | — | US | disclosed |
| US-20080181868-A1 | MACROCYLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-07-31 | — | — | US | disclosed |
| US-20080125444-A1 | ACYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-05-29 | — | — | US | disclosed |
| US-20080125444-A1 | ACYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-05-29 | — | — | US | disclosed |
| US-20070281885-A1 | MACROCYLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070281885-A1 | MACROCYLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090035271-A1 | TETRAZOLYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | TMPRSS4, PRSS1, SPINT2 | AAK1 3341/4885GAA 751/4885EPHX1 1473/4885 |
| US-20080125444-A1 | ACYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | CPN1, HPN, HCCS | AAK1 3596/4885GAA 497/4885EPHX1 410/4885 |
| US-20080181868-A1 | MACROCYLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | HCCS, CPN1, HPN | AAK1 4054/4885GAA 630/4885EPHX1 453/4885 |
| US-20070281885-A1 | MACROCYLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | HCCS, CPN1, HPN | AAK1 4054/4885GAA 630/4885EPHX1 453/4885 |
| US-20090130059-A1 | TETRAZOLYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | TMPRSS4, PRSS1, SPINT2 | AAK1 3341/4885GAA 751/4885EPHX1 1473/4885 |
| US-20080187516-A1 | ACYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | CPN1, HPN, HCCS | AAK1 3596/4885GAA 497/4885EPHX1 410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.